Imbria Pharmaceuticals Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$66.7M
- Investors
-
8
Imbria Pharmaceuticals General Information
Description
Operator of a clinical-stage company designed to develop novel therapies for patients with life-altering cardiometabolic disorders. The company focused on restoring or improving the cell's ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits in non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction, enabling healthcare providers to provide medicine by altering the cellular metabolism and mitochondrial function.
Contact Information
Website
www.imbria.comCorporate Office
- 265 Franklin Street
- Suite 1702
- Boston, MA 02116
- United States
Corporate Office
- 265 Franklin Street
- Suite 1702
- Boston, MA 02116
- United States
Imbria Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 16-Dec-2025 | $66.7M | Completed | Clinical Trials - Phase 2 | ||
| 2. Early Stage VC (Series A) | 22-Jul-2020 | Completed | Clinical Trials - Phase 2 | |||
| 1. Seed Round | 02-Jul-2018 | $40.2M | $40.2M | Completed | Clinical Trials - Phase 2 |
Imbria Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-3 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | ||||||||
| Seed-1 | 13,639,285 | $0.000100 | $2.65 | $2.65 | 1x | $2.62 | 9.22% | |
| Seed | 8,473,683 | $0.000100 | $4.75 | $4.75 | 1x | $4.75 | 5.66% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Imbria Pharmaceuticals Comparisons
Industry
Financing
Details
Imbria Pharmaceuticals Competitors (4)
One of Imbria Pharmaceuticals’s 4 competitors is Cytokinetics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cytokinetics | Formerly VC-backed | South San Francisco, CA | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Gossamer Bio | Formerly VC-backed | San Diego, CA | ||||
| Milestone Pharmaceuticals | Formerly VC-backed | Montreal, Canada |
Imbria Pharmaceuticals Patents
Imbria Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4531845-A1 | Compounds and methods for increasing efficiency of cardiac metabolism | Pending | 03-Jun-2022 | ||
| EP-4531845-A4 | Compounds and methods for increasing efficiency of cardiac metabolism | Pending | 03-Jun-2022 | ||
| US-20250340523-A1 | Compounds and methods for increasing efficiency of cardiac metabolism | Pending | 03-Jun-2022 | ||
| WO-2023235297-A1 | Compounds and methods for increasing efficiency of cardiac metabolism | Inactive | 03-Jun-2022 | ||
| AU-2022376557-A1 | Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism | Pending | 01-Nov-2021 | A61K31/496 |
Imbria Pharmaceuticals Signals
Imbria Pharmaceuticals Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AN Venture Partners | Venture Capital | Minority | ||
| Catalio Capital Management | Venture Capital | Minority | ||
| Cytokinetics | Corporation | Minority | ||
| Deep Track Capital | Venture Capital | Minority | ||
| SV Health Investors | PE/Buyout | Minority |
Imbria Pharmaceuticals FAQs
-
When was Imbria Pharmaceuticals founded?
Imbria Pharmaceuticals was founded in 2018.
-
Where is Imbria Pharmaceuticals headquartered?
Imbria Pharmaceuticals is headquartered in Boston, MA.
-
What is the size of Imbria Pharmaceuticals?
Imbria Pharmaceuticals has 10 total employees.
-
What industry is Imbria Pharmaceuticals in?
Imbria Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Imbria Pharmaceuticals a private or public company?
Imbria Pharmaceuticals is a Private company.
-
What is the current valuation of Imbria Pharmaceuticals?
The current valuation of Imbria Pharmaceuticals is .
-
What is Imbria Pharmaceuticals’s current revenue?
The current revenue for Imbria Pharmaceuticals is .
-
How much funding has Imbria Pharmaceuticals raised over time?
Imbria Pharmaceuticals has raised $152M.
-
Who are Imbria Pharmaceuticals’s investors?
AN Venture Partners, Catalio Capital Management, Cytokinetics, Deep Track Capital, and SV Health Investors are 5 of 8 investors who have invested in Imbria Pharmaceuticals.
-
Who are Imbria Pharmaceuticals’s competitors?
Cytokinetics, Altimmune, Gossamer Bio, and Milestone Pharmaceuticals are competitors of Imbria Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process